ArticleExperimental and therapeutic medicine2017
CaMKII: The molecular villain that aggravates cardiovascular disease.
Article in Experimental and therapeutic medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 38 citations in OpenAlex.
- CaPhysiological reports · 2026Article
- RNA Therapeutics in Heart Failure.Journal of cardiovascular translational research · 2025Review
- Reversing cardiac hypertrophy and heart failure using a cardiac targeting peptide linked to miRNA106a.Clinical and translational medicine · 2025Article
- Molecular Mechanisms of L-Type Calcium Channel Dysregulation in Heart Failure.International journal of molecular sciences · 2025Review
- Article
- Combined fructose and sucrose consumption from an early age aggravates cardiac oxidative damage and causes a dilated cardiomyopathy in SHR rats.Journal of clinical biochemistry and nutrition · 2023Article
- Molecular basis for cellular retinoic acid-binding protein 1 in modulating CaMKII activation.Frontiers in molecular biosciences · 2023Article
- The Importance of SGLT-2 Inhibitors as Both the Prevention and the Treatment of Diabetic Cardiomyopathy.Antioxidants (Basel, Switzerland) · 2022Review
- Non-canonical WNT signalling in cardiovascular disease: mechanisms and therapeutic implications.Nature reviews. Cardiology · 2022Review
- Reversing Cardiac Hypertrophy at the Source Using a Cardiac Targeting Peptide Linked to miRNA106a: Targeting Genes That Cause Cardiac Hypertrophy.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Impact and potential mechanism of effects of chronic moderate alcohol consumption on cardiac function in aldehyde dehydrogenase 2 gene heterozygous mice.Alcoholism, clinical and experimental research · 2022Article
- Review
- Exercise-induced signaling pathways to counteracting cardiac apoptotic processes.Frontiers in cell and developmental biology · 2022Review
- High uric acid promotes mitophagy through the ROS/CaMKIIδ/Parkin pathway in cardiomyocytesAmerican journal of translational research · 2021Article
- CaMKII-dependent ryanodine receptor phosphorylation mediates sepsis-induced cardiomyocyte apoptosis.Journal of cellular and molecular medicine · 2020Article
- Gene therapy for inherited arrhythmias.Cardiovascular research · 2020Review
- Tilianin Protects against Ischemia/Reperfusion-Induced Myocardial Injury through the Inhibition of the CaBioMed research international · 2020Article
- Arsenic is more potent than cadmium or manganese in disrupting the INS-1 beta cell microRNA landscape.Archives of toxicology · 2019Article
- Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia by Inhibition of CaCirculation · 2019Article
- [Inhibition of CaMKII alleviates myocardial ischemia?reperfusion injury by reducing mitochondrial oxidative stress in isolated perfused rat heart].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pathological remodeling of the myocardium is an integral part of the events that lead to heart failure (HF), which involves altered gene expression, disturbed signaling pathways and altered Ca
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.